Westfield Capital Management Co. LP Sells 189,474 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Westfield Capital Management Co. LP trimmed its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 9.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,739,874 shares of the company's stock after selling 189,474 shares during the quarter. Vaxcyte accounts for approximately 0.9% of Westfield Capital Management Co. LP's portfolio, making the stock its 20th largest holding. Westfield Capital Management Co. LP owned about 1.40% of Vaxcyte worth $198,815,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PCVX. RA Capital Management L.P. grew its position in Vaxcyte by 4.0% during the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company's stock valued at $560,398,000 after buying an additional 312,500 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company's stock worth $524,117,000 after purchasing an additional 692,492 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Vaxcyte by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock valued at $216,966,000 after purchasing an additional 498,359 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in Vaxcyte by 3.6% during the second quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company's stock valued at $146,093,000 after purchasing an additional 66,940 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Vaxcyte by 47.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock valued at $148,075,000 after purchasing an additional 419,600 shares during the period. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Price Performance

PCVX stock traded up $0.15 during midday trading on Friday, reaching $88.54. The company had a trading volume of 1,614,295 shares, compared to its average volume of 1,610,634. The firm has a 50-day moving average price of $107.89 and a 200-day moving average price of $89.57. The company has a market capitalization of $11.04 billion, a P/E ratio of -19.25 and a beta of 1.01. Vaxcyte, Inc. has a 1 year low of $48.24 and a 1 year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the firm posted ($0.91) earnings per share. On average, equities analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 7,098 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $109.21, for a total value of $775,172.58. Following the completion of the sale, the chief executive officer now directly owns 138,581 shares of the company's stock, valued at $15,134,431.01. The trade was a 4.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 42,000 shares of the firm's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. This trade represents a 31.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 102,464 shares of company stock valued at $11,455,576. Corporate insiders own 3.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Mizuho lifted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research note on Tuesday, September 10th. Bank of America increased their target price on Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.